Latanoprost Viatris

Latanoprost, the active ingredient in Latanoprost Viatris, is a prostaglandin analog presented as an ophthalmic solution for ocular use. It lowers intra‑ocular pressure and is indicated for primary open‑angle glaucoma and ocular hypertension in adult patients. The medication is formulated for once‑daily instillation and is widely used in ophthalmology practice.

GNH USA supplies Latanoprost Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across all markets. Our global logistics network supports timely delivery to diverse healthcare settings.

Latanoprost is a prostaglandin analog that reduces intra‑ocular pressure by enhancing aqueous humor outflow, making it a cornerstone therapy for several glaucoma‑related conditions. - Primary open‑angle glaucoma: lowers intra‑ocular pressure, helping to prevent optic nerve damage and visual field loss. - Ocular hypertension: reduces elevated eye pressure to levels that decrease the risk of developing glaucoma. - Secondary open‑angle glaucoma (including pseudoexfoliative glaucoma): improves outflow and controls pressure when other mechanisms are compromised.

Latanoprost may cause ocular and peri‑ocular changes, most of which are mild and reversible.

Common Side Effects: - Eye redness: mild conjunctival hyperemia. - Increased eyelash growth: longer, thicker lashes. - Darkening of iris color: gradual brownish pigmentation. - Eye irritation or foreign‑body sensation.

Serious or Rare Side Effects: - Uveitis or iritis: intra‑ocular inflammation. - Macular edema: swelling of the central retina.

Before and during treatment, certain precautions should be observed. - Measure baseline intra‑ocular pressure: obtain a reading before starting therapy. - Monitor iris color changes: assess periodically during treatment. - Avoid use in active ocular inflammation: contraindicated in uveitis. - Counsel patients on possible eyelash and skin pigmentation changes. - Store at room temperature: keep in original container, protect from light and moisture.

Latanoprost may interact with other ocular or systemic agents.

Major Interactions (Avoid): - Concurrent use of other prostaglandin analog eye drops: may increase ocular side‑effects. - Combination with systemic carbonic anhydrase inhibitors: additive IOP‑lowering effect requires monitoring. - Use with ocular beta‑blockers: additive pressure reduction may lead to excessive lowering.

Moderate Interactions (Monitor Closely): - Co‑administration with ocular corticosteroids: may diminish prostaglandin efficacy. - Wearing contact lenses: may cause deposits; advise removal before instillation.